Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 865 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relapsed, Refractory Multiple Myeloma Clear all

Conditions: Multiple Myeloma
Interventions: Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide, Elotuzumab, Dexamethasone; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Birmingham, Alabama • Milwaukee, Wisconsin

Conditions: Acute Leukemia, Chronic Myeloproliferative Disease, Chronic Lymphoproliferative Disease, Multiple Myeloma, Lymphoma, Poor-risk Myelodysplasia (MDS)
Interventions: ZIO-101 (Darinaparsin); Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions: Siltuximab, Teclistamab(FDA-approved); Drug
Lead sponsor: Jack Khouri, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Myeloma
Interventions: Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib, Daratumumab; Drug
Lead sponsor: Oncopeptides AB; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts • Columbus, Ohio

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: ALT-801; Biological
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Refractory Multiple Myeloma
Interventions: liposomal doxorubicin, bortezomib, dexamethasone, cyclophosphamide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 130
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 94 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: rituximab, lenalidomide, microarray analysis, flow cytometry, laboratory biomarker analysis; Biological · Drug · Genetic + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Etentamig, Iberdomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 7
States / cities: Beverly Hills, California • Denver, Colorado • St Louis, Missouri + 4 more

Conditions: Multiple Myeloma
Interventions: dexamethasone, thalidomide, lenalidomide; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: mRNA-2808; Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 6 more

Conditions: Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Elotuzumab, Iberdomide, Dexamethasone; Drug
Lead sponsor: Omar Nadeem, MD; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: bortezomib, pegylated liposomal doxorubicin hydrochloride, vorinostat; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 4
States / cities: New York, New York • Chapel Hill, North Carolina • Durham, North Carolina + 1 more

Conditions: Multiple Myeloma
Interventions: Motexafin Gadolinium Injection; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cancer, Neoplasms
Interventions: GSK2816126; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Multiple Myeloma
Interventions: Bortezomib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Mobile, Alabama • Detroit, Michigan • Toledo, Ohio

Conditions: Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions: Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion, Bendamustine, Fludarabine, Rituximab; Radiation · Procedure · Biological + 1 more
Lead sponsor: Noah Merin; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Other + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Up to 69 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 10
States / cities: Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more

Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions: BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Romidepsin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 12
States / cities: Loma Linda, California • Rancho Mirage, California • Santa Barbara, California + 9 more

Conditions: Multiple Myeloma
Interventions: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Bullhead City, Arizona • Los Angeles, California • Pembroke Pines, Florida + 8 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: ABBV-453, Dexamethasone, Daratumumab, Lenalidomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Stanford, California • Miami, Florida • New Orleans, Louisiana + 9 more

Conditions: B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma
Interventions: Samalizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: Tucson, Arizona • Atlanta, Georgia • Morristown, New Jersey + 1 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: UCARTCS1A; Biological
Lead sponsor: Cellectis S.A.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Atlanta, Georgia + 5 more

Conditions: Multiple Myeloma
Interventions: MK-3475, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Ashraf Badros; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

A Phase I Trial of ZIO-101 in Hematologic Cancers

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Trial of Romidepsin and Bortezomib for Multiple Myeloma

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma